Boston Scientific (NYSE:BSX) Releases FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 3.340-3.410 for the period, compared to the consensus EPS estimate of 3.450. The company issued revenue guidance of $21.5 billion-$21.8 billion, compared to the consensus revenue estimate of $22.2 billion. Boston Scientific also updated its Q2 2026 guidance to 0.820-0.840 EPS.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent analyst reports. JPMorgan Chase & Co. reduced their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Raymond James Financial reissued an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company set a $75.00 price target on shares of Boston Scientific in a report on Thursday. Finally, Morgan Stanley reduced their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.65.

Boston Scientific Trading Up 2.3%

Shares of BSX opened at $66.37 on Thursday. Boston Scientific has a fifty-two week low of $59.38 and a fifty-two week high of $109.50. The business has a 50-day moving average of $68.87 and a 200 day moving average of $86.16. The firm has a market cap of $98.64 billion, a P/E ratio of 34.19, a price-to-earnings-growth ratio of 0.92 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts forecast that Boston Scientific will post 3.45 EPS for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat: Boston Scientific reported Q1 revenue of $5.20B (+11.6% YoY) and adjusted EPS $0.80, modestly beating consensus — a demonstration of continued top‑line strength that supports medium‑term growth expectations. Press Release
• Positive Sentiment: Strong profit rebound: GAAP net income and operating performance improved sharply in Q1 (net income roughly doubled year‑over‑year), which underpins margins and ROE metrics cited in reports. WSJ: Net Grows Sharply
• Positive Sentiment: Options/institutional activity: Elevated call‑option buying and unusual options volume ahead of/from the print suggests speculative bullish positioning that can amplify intraday upside. Options Activity
• Neutral Sentiment: Analysts still largely positive: Several firms kept Buy/Outperform ratings (Jefferies, Barclays, etc.) even as they trimmed price targets — that maintains long‑term support while trimming near‑term upside. Jefferies Coverage
• Neutral Sentiment: Multiple PT cuts but ratings retained: Firms (Truist, Baird, Needham, Barclays, Jefferies) trimmed targets — reduces headline upside but signals continued analyst conviction. Benzinga: PT Changes
• Negative Sentiment: Guidance cut: Management lowered Q2 and FY 2026 EPS and revenue guidance (Q2 EPS 0.82–0.84 vs. ~0.86 consensus; FY EPS 3.34–3.41 vs. ~3.45 consensus), trimming near‑term growth expectations and sparking profit‑forecast concern. Reuters: Cuts Forecast
• Negative Sentiment: Class‑action legal risk: Multiple law firms and investor alerts allege misstatements about electrophysiology demand during a defined class period — a wave of filings/solicitations raises litigation risk, potential distraction and possible future costs. PRNewswire: Investor Alert
• Negative Sentiment: Market sentiment/technical pressure: Shares hit a 52‑week low in the lead‑up to earnings as analysts trimmed forecasts — standing risk of continued downside if guidance disappointment persists. Blockonomi: 52‑Week Low

Institutional Investors Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the stock. Maverick Capital Ltd. bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $280,735,000. Farallon Capital Management LLC increased its holdings in Boston Scientific by 56.7% during the 4th quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after acquiring an additional 2,693,007 shares during the period. Marshall Wace LLP lifted its stake in Boston Scientific by 30.7% in the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares in the last quarter. Morgan Stanley lifted its stake in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Finally, Credit Agricole S A bought a new position in Boston Scientific in the 3rd quarter valued at $204,812,000. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.